NASDAQ:NBSE

NeuBase Therapeutics Competitors

$6.50
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.44
Now: $6.50
$6.87
50-Day Range
$6.50
MA: $8.61
$11.00
52-Week Range
$6.44
Now: $6.50
$12.89
Volume221,570 shs
Average Volume307,504 shs
Market Capitalization$150.67 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41

Competitors

NeuBase Therapeutics (NASDAQ:NBSE) Vs. MGTA, EOLS, RLMD, ANAB, ALDX, and MRNS

Should you be buying NBSE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to NeuBase Therapeutics, including Magenta Therapeutics (MGTA), Evolus (EOLS), Relmada Therapeutics (RLMD), AnaptysBio (ANAB), Aldeyra Therapeutics (ALDX), and Marinus Pharmaceuticals (MRNS).

Magenta Therapeutics (NASDAQ:MGTA) and NeuBase Therapeutics (NASDAQ:NBSE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares Magenta Therapeutics and NeuBase Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95
NeuBase TherapeuticsN/AN/A$-17,390,000.00($0.89)-7.30

NeuBase Therapeutics is trading at a lower price-to-earnings ratio than Magenta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Magenta Therapeutics and NeuBase Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
NeuBase Therapeutics00403.00

Magenta Therapeutics currently has a consensus target price of $17.6667, suggesting a potential upside of 43.40%. NeuBase Therapeutics has a consensus target price of $17.3333, suggesting a potential upside of 166.67%. Given NeuBase Therapeutics' higher possible upside, analysts clearly believe NeuBase Therapeutics is more favorable than Magenta Therapeutics.

Institutional and Insider Ownership

59.3% of Magenta Therapeutics shares are held by institutional investors. Comparatively, 29.0% of NeuBase Therapeutics shares are held by institutional investors. 10.9% of Magenta Therapeutics shares are held by insiders. Comparatively, 24.0% of NeuBase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Magenta Therapeutics and NeuBase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
NeuBase TherapeuticsN/A-90.43%-77.20%

Volatility and Risk

Magenta Therapeutics has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, NeuBase Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Summary

Magenta Therapeutics beats NeuBase Therapeutics on 5 of the 9 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and NeuBase Therapeutics (NASDAQ:NBSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Evolus and NeuBase Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26
NeuBase TherapeuticsN/AN/A$-17,390,000.00($0.89)-7.30

NeuBase Therapeutics has lower revenue, but higher earnings than Evolus. NeuBase Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Evolus and NeuBase Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14402.33
NeuBase Therapeutics00403.00

Evolus currently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. NeuBase Therapeutics has a consensus target price of $17.3333, suggesting a potential upside of 166.67%. Given NeuBase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuBase Therapeutics is more favorable than Evolus.

Institutional & Insider Ownership

21.7% of Evolus shares are held by institutional investors. Comparatively, 29.0% of NeuBase Therapeutics shares are held by institutional investors. 10.1% of Evolus shares are held by company insiders. Comparatively, 24.0% of NeuBase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Evolus and NeuBase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
NeuBase TherapeuticsN/A-90.43%-77.20%

Risk & Volatility

Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, NeuBase Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

NeuBase Therapeutics beats Evolus on 8 of the 12 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and NeuBase Therapeutics (NASDAQ:NBSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Relmada Therapeutics and NeuBase Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-16.31
NeuBase TherapeuticsN/AN/A$-17,390,000.00($0.89)-7.30

Relmada Therapeutics is trading at a lower price-to-earnings ratio than NeuBase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Relmada Therapeutics and NeuBase Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
NeuBase Therapeutics00403.00

Relmada Therapeutics currently has a consensus target price of $63.3333, suggesting a potential upside of 79.77%. NeuBase Therapeutics has a consensus target price of $17.3333, suggesting a potential upside of 166.67%. Given NeuBase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuBase Therapeutics is more favorable than Relmada Therapeutics.

Institutional & Insider Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 29.0% of NeuBase Therapeutics shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Comparatively, 24.0% of NeuBase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Relmada Therapeutics and NeuBase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
NeuBase TherapeuticsN/A-90.43%-77.20%

Risk & Volatility

Relmada Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, NeuBase Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

NeuBase Therapeutics beats Relmada Therapeutics on 6 of the 10 factors compared between the two stocks.

AnaptysBio (NASDAQ:ANAB) and NeuBase Therapeutics (NASDAQ:NBSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Risk & Volatility

AnaptysBio has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, NeuBase Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for AnaptysBio and NeuBase Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
NeuBase Therapeutics00403.00

AnaptysBio currently has a consensus target price of $30.2857, suggesting a potential upside of 45.12%. NeuBase Therapeutics has a consensus target price of $17.3333, suggesting a potential upside of 166.67%. Given NeuBase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuBase Therapeutics is more favorable than AnaptysBio.

Earnings and Valuation

This table compares AnaptysBio and NeuBase Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million71.39$-97,340,000.00($3.60)-5.80
NeuBase TherapeuticsN/AN/A$-17,390,000.00($0.89)-7.30

NeuBase Therapeutics has lower revenue, but higher earnings than AnaptysBio. NeuBase Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AnaptysBio and NeuBase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
NeuBase TherapeuticsN/A-90.43%-77.20%

Institutional & Insider Ownership

29.0% of NeuBase Therapeutics shares are held by institutional investors. 13.0% of AnaptysBio shares are held by company insiders. Comparatively, 24.0% of NeuBase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NeuBase Therapeutics beats AnaptysBio on 9 of the 12 factors compared between the two stocks.

NeuBase Therapeutics (NASDAQ:NBSE) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Risk and Volatility

NeuBase Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for NeuBase Therapeutics and Aldeyra Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeuBase Therapeutics00403.00
Aldeyra Therapeutics011002.91

NeuBase Therapeutics presently has a consensus price target of $17.3333, suggesting a potential upside of 166.67%. Aldeyra Therapeutics has a consensus price target of $26.00, suggesting a potential upside of 115.95%. Given NeuBase Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe NeuBase Therapeutics is more favorable than Aldeyra Therapeutics.

Earnings & Valuation

This table compares NeuBase Therapeutics and Aldeyra Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuBase TherapeuticsN/AN/A$-17,390,000.00($0.89)-7.30
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-5.87

NeuBase Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NeuBase Therapeutics and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeuBase TherapeuticsN/A-90.43%-77.20%
Aldeyra TherapeuticsN/A-73.73%-52.74%

Institutional & Insider Ownership

29.0% of NeuBase Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are held by institutional investors. 24.0% of NeuBase Therapeutics shares are held by company insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

NeuBase Therapeutics beats Aldeyra Therapeutics on 6 of the 11 factors compared between the two stocks.

NeuBase Therapeutics (NASDAQ:NBSE) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Risk and Volatility

NeuBase Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for NeuBase Therapeutics and Marinus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeuBase Therapeutics00403.00
Marinus Pharmaceuticals00903.00

NeuBase Therapeutics presently has a consensus price target of $17.3333, suggesting a potential upside of 166.67%. Marinus Pharmaceuticals has a consensus price target of $28.75, suggesting a potential upside of 85.24%. Given NeuBase Therapeutics' higher possible upside, research analysts plainly believe NeuBase Therapeutics is more favorable than Marinus Pharmaceuticals.

Earnings & Valuation

This table compares NeuBase Therapeutics and Marinus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuBase TherapeuticsN/AN/A$-17,390,000.00($0.89)-7.30
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($3.96)-3.92

NeuBase Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NeuBase Therapeutics and Marinus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeuBase TherapeuticsN/A-90.43%-77.20%
Marinus PharmaceuticalsN/A-95.56%-66.01%

Institutional & Insider Ownership

29.0% of NeuBase Therapeutics shares are held by institutional investors. Comparatively, 79.3% of Marinus Pharmaceuticals shares are held by institutional investors. 24.0% of NeuBase Therapeutics shares are held by company insiders. Comparatively, 2.8% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


NeuBase Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32flat$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58flat$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23flat$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87flat$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04flat$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52flat$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07flat$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44flat$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26flat$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20flat$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56flat$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10flat$544.91 million$26.74 million17.75
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66flat$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04flat$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24flat$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32flat$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87flat$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28flat$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04flat$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44flat$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78flat$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00flat$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97flat$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00flat$502.28 million$58.12 million-16.28
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.72flat$500.13 million$57.49 million-6.49
XBiotech logo
XBIT
XBiotech
1.0$16.95flat$499.33 millionN/A1.17
AC Immune logo
ACIU
AC Immune
1.3$6.87flat$494.21 million$111.75 million-7.63
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.53flat$494.19 millionN/A-2.59Gap Down
Altimmune logo
ALT
Altimmune
1.9$12.90flat$479.24 million$5.80 million-6.48
Akouos logo
AKUS
Akouos
1.6$13.87flat$477.16 millionN/A0.00News Coverage
Verastem logo
VSTM
Verastem
1.1$2.76flat$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07flat$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48flat$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.18flat$469.72 million$6.68 million-5.04
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.06flat$469.72 million$335 million-1.03Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.63flat$466.82 million$56.50 million0.00Analyst Upgrade
Gap Up
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.57flat$465.95 million$6.07 million-3.62Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23flat$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
BCEL
Atreca
1.7$12.29flat$452.65 millionN/A-4.36Gap Down
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.29flat$452.48 millionN/A0.00Gap Up
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.33flat$449.56 million$102.31 million6.46
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.02flat$446.29 millionN/A0.00News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8N/AN/A$439.81 millionN/A-3.55
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.92flat$438.87 millionN/A-12.08News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$38.99flat$438.75 million$18.37 million-35.13Analyst Upgrade
Sesen Bio logo
SESN
Sesen Bio
1.2$2.52flat$426.85 millionN/A-5.73Gap Down
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.45flat$426.64 million$380,000.000.00Analyst Upgrade
DURECT logo
DRRX
DURECT
1.4$1.85flat$420.32 million$29.56 million-36.99
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.66flat$415.41 million$9.48 million-0.28
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$8.26flat$407.75 million$2.42 million-7.25Analyst Report
Unusual Options Activity
Analyst Revision
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.